3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Neoplasms
2
Interventions
pembrolizumab
94
Paclitaxel
85
Gemcitabine
83
Carboplatin
79
Docetaxel
60
Cisplatin
58
Bevacizumab
58
Nivolumab
56
Fluorouracil
47
Capecitabine
46
Magnetic Resonance Spectroscopy
44
Radiotherapy
41
Irinotecan
40
Oxaliplatin
38
Erlotinib Hydrochloride
37
Pemetrexed
34
Leucovorin
34
Biopsy
34
atezolizumab
33
Cetuximab
32
Standard of Care
31
Trastuzumab
28
Cyclophosphamide
28
Radiosurgery
27
Blood Specimen Collection
27
Specimen Handling
26
Sorafenib
26
Ipilimumab
26
Everolimus
26
olaparib
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Aftercare
×
Tumor-Agnostic
×
Clear all
NCT02637349
2019-11-26
POST
Polaris Health Directions
Phase 2
Completed
200 enrolled
NCT02440737
2019-10-18
NEST
Vanderbilt-Ingram Cancer Center
Phase NA
Terminated
67 enrolled